Same molecule, different paths: Where value goes in cross-border dealmaking in a new era

A growing share of the molecules Big Pharma licenses and buys now originates outside the United States. In this new era of cross-border dealmaking, an innovative asset can command dramatically different amounts depending on how the deal is structured. PharmCube brings a data-built map of cross-border dealmaking to a panel of multinational buyers — both US and ex-US biotechs — and cross-border investors, to ask where value accrues and who keeps it. This session will explore:

• Deal structures channeling ex-US innovation into US pharma and factors driving a buyer's choice
• The distinct capabilities US and ex-US biotechs bring to the table
• How value is distributed across a deal, and who ultimately captures it